Articles Tagged With: cannabidiol
-
Efficacy and Safety of Cannabidiol in Treatment of Focal Seizures Associated with Tuberous Sclerosis Complex
Cannabidiol used as an add-on therapy for intractable focal seizures in patients with tuberous sclerosis complex was efficacious. Cannabidiol also had an acceptable adverse event profile, but frequently induced transient elevation of liver enzymes.
-
Understanding Cannabidiol (CBD)
Cannabidiol is used by a growing population for many ailments. Although not typically an emergency drug, it has important interactions and a few side effects that can be seen in the emergency department.
-
The ABCs of CBD: The Fundamentals of Cannabidiol
Cannabidiol (CBD) is one of two major constituents of marijuana and is the non-psychoactive component of cannabis. As its popularity has grown, questions about CBD from patients to their primary care clinicians have increased dramatically. As a patient advocate interpreting the available evidence, the primary care clinician needs to recognize how CBD differs from marijuana, what its clinical utility might be, and what its risks are.
-
Cannabidiol: Does It Help in Drug-resistant Epileptic Encephalopathies?
In this double-blind, placebo-controlled trial, the authors investigated the efficacy of adjunctive cannabidiol in a population of severe developmental epileptic encephalopathies and found some efficacy.
-
Ethics and Science, Cannabinoids and Healthcare
Perhaps no topic is more controversial than the use of marijuana in clinical practice. Within the United States, there are an estimated 55 million recent active users, defined as one to two uses within the previous year, and 35 million regular users, defined as one to two uses per month.
-
Topical Cannabis for Wound Pain: A Case Series
For three people with continued pain despite conventional treatment for pyoderma gangrenosum, topical cannabis led to statistically significant pain relief for two of them.
-
Randomized Trial of Cannabidiol for Medically Refractory Seizures in Dravet Syndrome
In a double-blind study, 120 children and young adults with the Dravet syndrome and medically refractory seizures were assigned randomly to receive either cannabidiol or placebo, as well as their usual antiepileptic drugs/therapies. The primary finding was a significant decrease in convulsive seizure frequency during the 14-week treatment period for patients receiving cannabidiol compared to those receiving placebo.